ReNeuron Group Plc (LON RENE) opened at 1.70 on Monday. The firm has a 50 day moving average of GBX 1.73 and a 200 day moving average of GBX 1.92. ReNeuron Group Plc has a 12-month low of GBX 1.65 and a 12-month high of GBX 3.67. The firm’s market capitalization is GBX 53.80 million.
COPYRIGHT VIOLATION WARNING: “N+1 Singer Reaffirms “corporate” Rating for ReNeuron Group Plc (RENE)” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/n1-singer-reaffirms-corporate-rating-for-reneuron-group-plc-rene/1704099.html.
About ReNeuron Group Plc
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).
Receive News & Ratings for ReNeuron Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group Plc and related companies with our FREE daily email newsletter.